QMF149
Sponsors
Novartis Pharma AG, Novartis Pharmaceuticals, University Medical Center Groningen
Conditions
Allergic AsthmaAsthmaCOPD
Phase 2
Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01636076
Start: 2012-11-30End: 2013-09-30Updated: 2014-11-17
Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to < 12 Years Old With Asthma
CompletedNCT04589663
Start: 2021-06-07End: 2022-04-11Updated: 2023-10-13
Phase 3
A Long-term Safety Study of QMF149 in Japanese Participants With Asthma
CompletedNCT03100500
Start: 2017-04-25End: 2019-02-12Updated: 2020-02-07
Anti-inflammatory Effects Glycopyrronium
CompletedNCT04259164
Start: 2020-09-10End: 2022-12-29Updated: 2023-01-12
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
RecruitingNCT05562466
Start: 2023-05-11End: 2028-05-30Target: 200Updated: 2026-07-13
Double-blind, randomized, active-controlled, two-way cross-over study, with 12-week treatment duration per period, to evaluate the efficacy and safety of QMF149 (indacaterol acetate / mometasone furoate) compared to budesonide in children from 6 to less than 12 years of age with asthma
RecruitingCTIS2022-501899-26-00
Start: 2023-09-01Target: 94Updated: 2025-10-30